ZXZhiqiang Xiao

Zhiqiang Xiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhiqiang Xiao has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De novo biosynthesis of eriocitrin in Saccharomyces cerevisiae through deep learning-guided enzyme screening and systematic metabolic engineering

    by Qiyuan Lu, Xinjia Tan, Siqi Zhang, Yongtong Wang, Yifei Zhao, Juan Liu, Fanglin Hu, Shasha Zuo, Jiaxu Chen, Liusha Fan, et al.

    Eriocitrin, a flavanone-7-O-disaccharide known for its antioxidant and anti-inflammatory properties, holds considerable promise for use in functional foods and pharmaceuticals. However, its large-scale production is constrained by the limitations of conventional plant extraction, including low abundance of active compounds and seasonal variability. Here, we established a de novo biosynthetic pathway for eriocitrin from glucose in engineered Saccharomyces cerevisiae through combinatorial metabolic engineering. First, to verify the feasibility of glycosylation in the eriocitrin synthesis process, two highly efficient flavonoid-7-O-glucosyltransferases were identified using an integrated bioinformatics and deep learning approach. Subsequently, through the reconstruction of the UDP-rhamnose synthesis pathway and enhancement of the key glycosylation precursor UDP-glucose supply, an eriocitrin titer of 147.9 mg/L was achieved following supplementation with 300 mg/L eriodictyol. To further achieve the de novo synthesis of eriocitrin, an eriodictyol-producing strain was developed by screening the optimal F3′H/CPR pair, engineering promoters, and pathway integration, achieving an eriodictyol titer of 237.8 mg/L. Finally, combining the eriodictyol-producing chassis strain with the previously optimized glycosylation module enabled the de novo production of eriocitrin, reaching a titer of 30.5 mg/L. This work demonstrates a proof-of-concept for microbial production of flavonoid disaccharides, providing a foundation for a sustainable and scalable supply of eriocitrin.


  • Modular pathway engineering enables gram-scale de novo biosynthesis of narirutin in yeast

    by Qiyuan Lu, Honghao Zhang, Xinjia Tan, Yongtong Wang, Yifei Zhao, Xuetong Xi, Shen Zhang, Fanglin Hu, Jiaxu Chen, Juan Liu, et al.


  • De Novo Biosynthesis of Biochanin A in Saccharomyces cerevisiae via Integrated Metabolic and Organelle Engineering

    by Xinjia Tan, Fanglin Hu, Shasha Zuo, Yongtong Wang, Zhiqiang Xiao, Siqi Zhang, Jiaxu Chen, Liusha Fan, Juan Liu, Yang Shan

    Biochanin A, a valuable O-methylated isoflavone, requires efficient P450 activity, regioselective methylation, and substantial cofactor availability. Here, we established a systematic strategy for its high-level production in Saccharomyces cerevisiae. We first constructed a genistein platform strain (16.10 mg/L) by optimizing the 2-hydroxyisoflavanone synthase gene (PlIFS) copy number. Next, a screen identified Pueraria lobata PlOMT9 as the optimal 4'-O-methyltransferase, yielding 14.29 mg/L biochanin A. As methylation was constrained by ATP supply, we augmented the cellular energy budget by expressing Vitreoscilla hemoglobin, increasing biochanin A titer to 19.48 mg/L. We then expanded the endoplasmic reticulum membrane capacity and coexpressed protein-folding chaperones, which profoundly enhanced the functional expression of the membrane-associated enzymes, skyrocketing the biochanin A titer to 39.89 mg/L. Finally, we increased the titer to 49.86 mg/L by improving the heme supply. The final strain in this study will facilitate the production of O-methylated isoflavones through the biochanin A biosynthetic pathway.


  • From Plants to Microbes: Harnessing Enzyme Promiscuity for Natural Product Synthesis

    by Fanglin Hu, Xinjia Tan, Shasha Zuo, Jiaxu Chen, Liusha Fan, Qiyuan Lu, Yifei Zhao, Yongtong Wang, Zhiqiang Xiao, Siqi Zhang, et al.

    Enzyme promiscuity has increasingly garnered significant attention in recent years, with a growing number of enzymes exhibiting this trait being progressively characterized. In plant systems, enzyme promiscuity critically underpins adaptive evolution, where evolutionary pressures drive environmental acclimatization and functional innovation. Conversely, in synthetic biology, this property exhibits a dual-edged nature: broad substrate promiscuity facilitates heterologous biosynthesis of natural products while enabling exploration of novel enzymatic functions and new natural product scaffolds. However, concomitant challenges─including byproduct accumulation, diminished target product purity, and reduced catalytic efficiency stemming from compromised specificity─impede industrial-scale natural product synthesis. Despite these limitations, this inherent enzymatic feature has driven synergistic advancements across biocatalysis, biosynthesis, and protein engineering. This review systematically dissects the manifestations of enzyme promiscuity in microbial natural product biosynthesis and critically evaluates contemporary strategies for alleviating enzyme promiscuity. Ultimately, it seeks to advance mechanistic understanding of enzyme promiscuity and establish a foundational framework for developing high-efficiency biosynthetic platforms.


  • Open Access

    Metabolic Engineering of Yeasts for the Production of the Triterpene Squalene: Current Status and Future Prospective

    by Shasha Zuo, Xinjia Tan, Jiwei Mao, Fanglin Hu, Jiaxu Chen, Liusha Fan, Qiyuan Lu, Yifei Zhao, Yongtong Wang, Zhiqiang Xiao, et al.

    Squalene, a linear triterpene compound characterized by its distinctive isoprenoid backbone with six transisoprene units, is widely used in the medicinal, nutraceutical, and cosmetic industries. The escalating global demand for squalene, coupled with growing ethical concerns over shark-derived sources and the inherent limitations of plant extraction (low yield) and chemical synthesis (environmental burden), has propelled microbial biosynthesis as a sustainable alternative. While substantial progress has been made in elucidating the mevalonate pathway and regulatory mechanisms of squalene biosynthesis, achieving industrially viable titers through microbial platforms remains an unresolved challenge. This review systematically summarizes recent advances in squalene biosynthesis using yeast chassis, with a focus on metabolic engineering strategies implemented in Saccharomyces cerevisiae and Yarrowia lipolytica. Furthermore, we elaborated on how squalene yields a diverse array of downstream derivatives through intricate enzymatic reactions. These derivatives—including triterpenoid saponins, triterpenoid acids, and steroids—exhibit significant applications in the pharmaceutical, nutraceutical, and cosmetic sectors. By integrating systems metabolic engineering with emerging synthetic biology tools, this work provides a roadmap for advancing strain engineering toward economically feasible squalene biomanufacturing.


  • Xylose-Driven Metabolic Reprogramming in Saccharomyces cerevisiae for Enhancing p-Coumaric Acid Production

    by Yifei Zhao, Zhiqiang Xiao, Yongtong Wang, Xinjia Tan, Siqi Zhang, Qiyuan Lu, Fanglin Hu, Shasha Zuo, Yang Shan, Juan Liu, et al.

    Xylose, the second most abundant sugar in nature, has garnered increasing attention as a promising carbon source for microbial fermentation in recent years. However, the unpredictable and inefficient metabolism of xylose in Saccharomyces cerevisiae has limited its practical application. In this study, we developed a xylotrophic strain through strategic integration of the xylose isomerase pathway, increasing xylose isomerase activity and identifying optimal transporters. Characterization of the modified strain demonstrated an 11.84-fold increase in ATP content under xylose conditions compared to glucose. This was achieved by redirecting carbon flux away from glycolysis, which resulted in a reduced level of ethanol and glycerol production. To demonstrate the industrial relevance of this platform, we applied the optimized strain to synthesize p-coumaric acid (p-CA). After process refinement, the strain achieved a final titer of 1293.15 mg/L p-CA using xylose as the sole carbon source, representing a 68.29% yield improvement compared to the glucose mode. To the best of our knowledge, this represents the highest reported to date for p-CA production from xylose alone. This study highlights the metabolic advantages of xylotrophic yeast and demonstrates the potential of leveraging these advantages for efficient p-CA synthesis, paving the way for the sustainable valorization of xylose into high-value natural products.


  • Open Access

    Sucrose-driven carbon redox rebalancing eliminates the Crabtree effect and boosts energy metabolism in yeast

    by Zhiqiang Xiao, Yifei Zhao, Yongtong Wang, Xinjia Tan, Lian Wang, Jiwei Mao, Siqi Zhang, Qiyuan Lu, Fanglin Hu, Shasha Zuo, et al.

    Saccharomyces cerevisiae primarily generates energy through glycolysis and respiration. However, the manifestation of the Crabtree effect results in substantial carbon loss and energy inefficiency, which significantly diminishes product yield and escalates substrate costs in microbial cell factories. To address this challenge, we introduce the sucrose phosphorolysis pathway and delete the phosphoglucose isomerase gene PGI1, effectively decoupling glycolysis from respiration and facilitating the metabolic transition of yeast to a Crabtree-negative state. Additionally, a synthetic energy system is engineered to regulate the NADH/NAD+ ratio, ensuring sufficient ATP supply and maintaining redox balance for optimal growth. The reprogrammed yeast strain exhibits significantly higher yields of various non-ethanol compounds, with lactic acid and 3-hydroxypropionic acid production increasing by 8- to 11-fold comparing to the conventional Crabtree-positive strain. This study describes an approach for overcoming the Crabtree effect in yeast, substantially improving energy metabolism, carbon recovery, and product yields.


  • Systematic Engineering of Eriodictyol-7-O-glucoside Biosynthetic Pathway through Enzyme Screening and Gene Regulation

    by Siqi Zhang, Feiyao Xiao, Juan Liu, Zhiqiang Xiao, Xinjia Tan, Yongtong Wang, Yifei Zhao, Qiyuan Lu, Shasha Zuo, Fanglin Hu, et al.

    The natural product eriodictyol-7-O-glucoside is more water-soluble and stable than eriodictyol and also exhibits novel biological activities and functions. However, its biosynthesis is hindered by the limited catalytic efficiency of key enzymes. Furthermore, the intricate interplay between cell growth and UDP-glucose supply adds another layer of complexity, rendering the engineering of productive strains challenging. To address this challenge, we introduced a novel "top-down" strategy in which bioinformatics analysis was initially used to identify six specific flavonoid 7-O-glucosyltransferases uniquely capable of converting eriodictyol into its 7-O-glucoside derivative. By manipulation of the plasmid copy number and promoter strength, the expression levels of the most promising flavonoid 7-O-glucosyltransferases from Arabidopsis thaliana were precisely fine-tuned, resulting in a remarkable 66.16% increase in eriodictyol-7-O-glucoside production. To improve the enhancement process, we focused on the overexpression of two pivotal enzymes: phosphoglucose mutase (encoded by the pgm gene) and UDP-glucose pyrophosphorylase (encoded by the galU gene). This strategic step was implemented to significantly increase the availability of glycosylation donors. Moreover, the eriodictyol concentration was increased to ensure ample feedstock. Finally, through comprehensive optimization of the fermentation conditions, eriodictyol-7-O-glucoside production was substantially enhanced, with a staggering 1187.36 mg L-1 obtained (molar conversion rate: 94.99%) at a substrate titer of 800 mg L-1 eriodictyol after 48 h of fermentation. The best engineered strain produced 2.70 g L-1 of eriodictyol-7-O-glucoside in a 5 L bioreactor. This study provides an effective and sustainable method for the high-yield production of flavonoid glycoside derivatives.


  • Engineering Saccharomyces cerevisiae for De Novo Biosynthesis of 3′-Hydroxygenistein

    by Xinjia Tan, Zhiqiang Xiao, Siqi Zhang, Yongtong Wang, Yifei Zhao, Qiyuan Lu, Fanglin Hu, Shasha Zuo, Jiwei Mao, Juan Liu, et al.

    The polyhydroxy isoflavone 3'-hydroxygenistein (3'-OHG) has a wide range of pharmaceutical and nutraceutical benefits. Therefore, it is important to develop an efficient and sustainable method for 3'-OHG production. Here, we engineered the metabolic pathways of Saccharomyces cerevisiae to achieve de novo biosynthesis of 3'-OHG. First, we screened 2-hydroxyisoflavanone synthase (IFS), cytochrome P450 reductase, and 2-hydroxyisoflavanone dehydratase from different sources and optimized the best combination via promoter engineering. Next, we demonstrated that amplification of the rate-limiting enzyme PlIFS from Pueraria lobata improved genistein production. Increasing the availability of the cofactor heme further increased genistein titer to 44.55 ± 1.82 mg/L. Subsequently, screening and multicopy integration of isoflavone-3'-hydroxylase achieved 13.23 ± 0.27 mg/L 3'-OHG from 100 mg/L naringenin. Finally, 1.40 ± 0.02 mg/L 3'-OHG could be achieved via the de novo biosynthesis pathway. The final strain generated in this study will facilitate the production of polyhydroxy isoflavones via the 3'-OHG biosynthetic pathway.


  • Open Access

    Antioxidant Effects and Potential Mechanisms of Citrus reticulata ‘Chachi’ Components: An Integrated Approach of Network Pharmacology and Metabolomics

    by Jiahao Xiao, Tian Sun, Shengyu Jiang, Zhiqiang Xiao, Yang Shan, Tao Li, Zhaoping Pan, Qili Li, Fuhua Fu

    Citrus reticulata ‘Chachi’ (CRC), recognized for its considerable edible and medicinal significance, is a valuable source of metabolites beneficial to human health. This research investigates the metabolic distinctions and antioxidant properties across four different parts of CRC, using multivariate statistical analysis to interpret metabolomic data and network pharmacology to identify potential antioxidant targets and relevant signaling pathways. The results indicate considerable metabolic differences in different parts of the sample, with 1622 metabolites showing differential expression, including 816 secondary metabolites, primarily consisting of terpenoids (31.02%) and flavonoids (25.22%). The dried mature citrus peel (CP) section demonstrates the highest level of total phenolics (6.8 mg/g), followed by the pulp without seed (PU) (4.52 mg/g), pulp with seed (PWS) (4.26 mg/g), and the seed (SE) (2.16 mg/g). Interestingly, targeted high-performance liquid chromatography of flavonoids reveals the highest level of nobiletin and tangeretin in CP, whereas PU has the highest level of hesperidin, narirutin, and didymin. Furthermore, all four sections of CRC exhibit robust antioxidant properties in in vitro assessments (CP > PU > PWS > SE). Lastly, the network pharmacology uncovered potential antioxidant mechanisms in CRC. This research offers deeper insights into the development and utilization of byproducts in the CRC processing industry.